Kymera Therapeutics (KYMR) Insider Booth Sells $141K of Stock
Bruce Booth sold 1,408 shares of Kymera Therapeutics in a planned transaction valued at approximately $140,772.
Reviewed by automated data checks against the source filing. How we make and check alerts
Bruce Booth sold 1,408 shares of Kymera Therapeutics, Inc. ($KYMR) at an average price of $99.98, worth about $140,771.84, on June 23, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $KYMR is up 16.7% after 1 week, up 12.3% after 1 month and up 6.7% to date (from the $98.25 close on Jun 23, 2026).
KYMR
Kymera Therapeutics, Inc.
Key Points
- On June 23, 2026, Bruce Booth sold 1,408 shares of Kymera Therapeutics for about $140,772, with the shares priced at $99.98 each.
- Kymera Therapeutics has a market cap of about $9.68 billion, and its stock trades near its 52-week high of $130.05.
- Analysts maintain a strong buy consensus on Kymera, with price targets averaging around $138.64.
Get $KYMR trade alerts by text
We text you when insiders, Congress or big funds trade $KYMR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Kymera Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Kymera Therapeutics, Inc.
Bruce Booth sold 1,408 shares of Kymera Therapeutics, Inc. (NasdaqGM: KYMR) on June 23, 2026, in a planned transaction valued at approximately $140,772. The shares sold for an average price of $99.98 each. This sale is part of a series of transactions by Booth, who continues to manage his holdings in the company.
More from Bruce Booth
This isn't Booth's only recent sale. Just two days later, on June 25, 2026, he sold 548,321 shares for about $65.1 million. Earlier, on June 18, 2026, he sold 115,056 shares at an average price of $91.01, totaling around $10.5 million. On June 22, 2026, he sold 278,128 shares for about $27.6 million. These transactions show Booth's ongoing strategy to adjust his stake in Kymera, a company focused on developing therapies that target disease-causing proteins.
Kymera's Stock Performance
Kymera Therapeutics' stock is currently trading at around $116.46, close to its 52-week high of $130.05. The shares have shown volatility recently, with a low of $50.35 in the past year. The average price over the last 50 days is $114.36, suggesting some stability in the near term. This recent trading activity comes as analysts remain bullish on the stock, with a consensus strong buy rating and a mean price target of approximately $138.64.
Analysts Set New Price Targets
On October 9, 2026, Raymond James initiated coverage on Kymera with an outperform rating and a price target of $140. Prior to that, Citigroup maintained its buy rating on October 5, 2026, raising its target to $150 from $135. Stifel also maintained a buy rating on September 22, 2026, with a target of $152. Other firms, including B of A Securities and Guggenheim, have recently reaffirmed their buy ratings, indicating strong confidence in the company's potential.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It specializes in developing small molecule therapeutics that degrade disease-causing proteins. The company is currently advancing several drug candidates for various conditions, including atopic dermatitis and autoimmune diseases.
What's Ahead for Kymera Therapeutics, Inc.
Investors will be watching for further insider activity and the upcoming earnings report scheduled for November 3, 2026. The recent 13F filings reflect past holdings and may not represent current positions, but they provide insight into the company's management strategies and market sentiment.
Related Filing Alerts
Source: Bruce Booth's Form 4 filing on $KYMR (Jun 23, 2026). Find the original filing: KYMR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts